Industry News
Pharmaceutical Industry News
GLP-1 giant Eli Lilly has once…
GLP-1 giant Eli Lilly has once again taken to the medium of short film to get an important message about obesity across.
The new chairman of the CDC’s…
The new chairman of the CDC's Advisory Committee on Immunization Practices, Kirk Milhoan, M.D., Ph.D., recently took to the podcast “Why Should I Trust You” to answer exactly that.
ST Pharm has struck a $56 million…
ST Pharm has struck a $56 million deal with an undisclosed U.S.-based biotech to produce active pharmaceutical ingredients (APIs) for a new oligonucleotide treatment. The Korean CDMO revealed the contract Friday in a regulatory filing.
A potential inflection point that…
A potential inflection point that Bausch Health hoped could diversify its portfolio has vanished with a pair of phase 3 failures for a new formulation of the company’s bread-and-butter Xifaxan—a setback that leaves a $2
In the second week of oral…
In the second week of oral Wegovy’s launch, which ended Jan. 16, the obesity pill logged roughly 18,400 total prescriptions, according to IMS data cited by Jefferies. That performance is a fair bit better than
¿Tu botiquín es un desastre?
Tener los medicamentos básicos adecuados puede facilitar el tratamiento de algunos malestares en casa.
Plotting a challenge to…
Plotting a challenge to Regeneron’s blockbuster Eylea, Ocular Therapeutix has hired “a key architect” of its rival’s launch to head its commercial team.
Big Insurers Try to Shift Blame for High Health Costs to Hospitals and Drug Makers
At two congressional hearings, lawmakers slammed executives of major companies, saying they were failing to rein in the cost of medical care for consumers.
Astellas CEO said he doesn’t want…
Astellas CEO said he doesn't want to make acquisitions simply to fill a revenue gap. Takeda is preparing for Trintellix's U.S. patent expiry with a round of layoffs. Chugai's CEO is seeking name recognition as
Express Scripts and the Federal…
Express Scripts and the Federal Trade Commission have officially reached a settlement in an ongoing case over insulin prices, with the PBM agreeing to a slew of business changes.
While the threat of U.S. import…
While the threat of U.S. import tariffs prompted a surge in drug production last year, that output is slated to slow across multiple geographies in 2026, according to a new report from financial services firm
Some Immune Systems Defeat Cancer. Could That Become a Drug?
Researchers found an antibody that seems to play a role in people with better lung cancer prognoses, but turning it into a treatment could be difficult.
As Lindsey Vonn’s comeback run…
As Lindsey Vonn’s comeback run heads toward a peak with Team USA at the upcoming 2026 Winter Olympics, Invivyd is adding the professional skier to its team, too.
The project, which involves Merck,…
The project, which involves Merck, SK Biosciences, Hilleman Laboratories and CDMO IDT Biologika, aims to make Merck's current Ebola vaccine easier to manufacture and store, prompting broader global accessibility.
Despite falling short in its…
Despite falling short in its recent bid to snatch Avadel from Alkermes, Lundbeck is signaling to investors that it’s not desperate for deals and will not lower its standards for future M&A transactions.
Fierce’s Zoey Becker, Angus Liu…
Fierce’s Zoey Becker, Angus Liu and Gabrielle Masson unpack the key topics and trends that stood out at this year’s J.P. Morgan Healthcare Conference.
After U.S. President Donald Trump…
After U.S. President Donald Trump took the stage at the World Economic Forum this week to tout the supposed success of his tariff-tinged trade negotiations, the French presidency has pushed back against a drug pricing
CDMO Samsung Biologics grew sales…
CDMO Samsung Biologics grew sales more than 30% last year to around 4.6 trillion Korean won ($3.1 billion) and lifted its 2025 operating profit to roughly 2.07 trillion won ($1.4 billion). Samsung Bio is now
Executives from top U.S….
Executives from top U.S. biosimilar makers are optimistic about the future of U.S. biosimilar adoption as recent FDA guidance seeks to streamline biosimilar development and potentially dissipate the upcoming “biosimilar void.”
Is Your Medicine Cabinet a Mess?
Here’s what to toss, what to keep and how to store your drugs safely.